229 related articles for article (PubMed ID: 2940265)
1. Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes.
Faaber P; Rijke TP; van de Putte LB; Capel PJ; Berden JH
J Clin Invest; 1986 Jun; 77(6):1824-30. PubMed ID: 2940265
[TBL] [Abstract][Full Text] [Related]
2. Binding of anti-DNA antibodies to glomerular heparan sulfate: a new clue for the pathogenesis of SLE nephritis?
Berden JH; Termaat RM; Brinkman K; Smeenk RJ; Swaak AJ; Faaber P; Assmann K; van de Heuvel LP; Veerkamp JH
Nephrologie; 1989; 10(3):127-32. PubMed ID: 2532712
[TBL] [Abstract][Full Text] [Related]
3. Heparan sulfate staining of the glomerular basement membrane in relation to circulating anti-DNA and anti-heparan sulfate reactivity: a longitudinal study in NZB/W F1 mice.
Hylkema MN; van Bruggen MC; van de Lagemaat R; Kramers K; Berden JH; Smeenk RJ
J Autoimmun; 1996 Feb; 9(1):41-50. PubMed ID: 8845053
[TBL] [Abstract][Full Text] [Related]
4. Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis.
Kalaaji M; Sturfelt G; Mjelle JE; Nossent H; Rekvig OP
Arthritis Rheum; 2006 Mar; 54(3):914-26. PubMed ID: 16508974
[TBL] [Abstract][Full Text] [Related]
5. Induction of systemic lupus erythematosus-like disease in mice by immunization with heparan sulfate.
Ofosu-Appiah W; Sfeir G; Viti D; Burashnikova E
Cell Immunol; 1998 Jan; 183(1):22-31. PubMed ID: 9578716
[TBL] [Abstract][Full Text] [Related]
6. Production and characterization of a monoclonal antibody against human glomerular heparan sulfate.
van den Born J; van den Heuvel LP; Bakker MA; Veerkamp JH; Assmann KJ; Berden JH
Lab Invest; 1991 Sep; 65(3):287-97. PubMed ID: 1890809
[TBL] [Abstract][Full Text] [Related]
7. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential.
Zhao Z; Weinstein E; Tuzova M; Davidson A; Mundel P; Marambio P; Putterman C
Arthritis Rheum; 2005 Feb; 52(2):522-30. PubMed ID: 15693007
[TBL] [Abstract][Full Text] [Related]
8. Possible pathogenic role of cationic anti-DNA autoantibodies in the development of nephritis in patients with systemic lupus erythematosus.
Suzuki N; Harada T; Mizushima Y; Sakane T
J Immunol; 1993 Jul; 151(2):1128-36. PubMed ID: 8335894
[TBL] [Abstract][Full Text] [Related]
9. Characterization of heparan sulfate isolated from drug glomerular basement membranes.
Linker A; Hovingh P; Kanwar YS; Farquhar MG
Lab Invest; 1981 Jun; 44(6):560-5. PubMed ID: 6453253
[TBL] [Abstract][Full Text] [Related]
10. Antigen-specificity of antibodies bound to glomeruli of mice with systemic lupus erythematosus-like syndromes.
Termaat RM; Assmann KJ; van Son JP; Dijkman HB; Koene RA; Berden JH
Lab Invest; 1993 Feb; 68(2):164-73. PubMed ID: 7680080
[TBL] [Abstract][Full Text] [Related]
11. Nephritogenicity of anti-proteoglycan antibodies in experimental murine lupus nephritis.
Kashihara N; Makino H; Szekanecz Z; Waltenbaugh CR; Kanwar YS
Lab Invest; 1992 Dec; 67(6):752-60. PubMed ID: 1460866
[TBL] [Abstract][Full Text] [Related]
12. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo.
Kramers C; Hylkema MN; van Bruggen MC; van de Lagemaat R; Dijkman HB; Assmann KJ; Smeenk RJ; Berden JH
J Clin Invest; 1994 Aug; 94(2):568-77. PubMed ID: 8040312
[TBL] [Abstract][Full Text] [Related]
13. Cross-reactivity of anti-ssDNA antibodies with heparan sulfate in patients with type I diabetes mellitus.
Triolo G; Giardina E; Scarantino G; Seddio G; Cardella F; Meli F; Bompiani G
Diabetes; 1989 Jun; 38(6):718-22. PubMed ID: 2524415
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes.
Termaat RM; Brinkman K; van Gompel F; van den Heuvel LP; Veerkamp JH; Smeenk RJ; Berden JH
J Autoimmun; 1990 Oct; 3(5):531-45. PubMed ID: 2252523
[TBL] [Abstract][Full Text] [Related]
15. Glomerular injury induced by antibodies against heparan sulfate proteoglycan (HSPG) derived from PYS 2 cells.
Yoshida F; Matsuo S; Hiramatsu T; Okura T; Yuzawa Y; Watanabe Y; Sakamoto N; Matsuo S
Nihon Jinzo Gakkai Shi; 1989 Feb; 31(2):135-43. PubMed ID: 2525633
[TBL] [Abstract][Full Text] [Related]
16. Decrease of heparan sulfate staining in the glomerular basement membrane in murine lupus nephritis.
van Bruggen MC; Kramers K; Hylkema MN; van den Born J; Bakker MA; Assmann KJ; Smeenk RJ; Berden JH
Am J Pathol; 1995 Mar; 146(3):753-63. PubMed ID: 7534044
[TBL] [Abstract][Full Text] [Related]
17. Anti-heparan sulfate antibody and functional loss of glomerular heparan sulfate proteoglycans in lupus nephritis.
Kim HJ; Hong YH; Kim YJ; Kim HS; Park JW; Do JY; Kim KJ; Bae SW; Kim CW; Lee CK
Lupus; 2017 Jul; 26(8):815-824. PubMed ID: 28420046
[TBL] [Abstract][Full Text] [Related]
18. Cross-reactivity of antiidiotypic antibodies with DNA in systemic lupus erythematosus.
Eivazova ER; McDonnell JM; Sutton BJ; Staines NA
Arthritis Rheum; 2000 Feb; 43(2):429-39. PubMed ID: 10693885
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes.
Shibata S; Sasaki T; Harpel P; Fillit H
Clin Immunol Immunopathol; 1994 Feb; 70(2):114-23. PubMed ID: 8299226
[TBL] [Abstract][Full Text] [Related]
20. Development of canine systemic lupus erythematosus model.
Choi E; Shin I; Youn H; Lee C
J Vet Med A Physiol Pathol Clin Med; 2004; 51(7-8):375-83. PubMed ID: 15533123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
